Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices

Nov 30 2017

• By Derrick Gingery

Alex Azar, Trump’s HHS secretary nominee, who spoke at the Senate HELP committee 11/29/17 — • Source: Ferdous Al-Faruque

Related Content

Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms

Nov 08 2004

Pay-For-Delay, REMS Reform Legislation Making (Slow) Progress In House

Jul 28 2017

Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing

Oct 18 2017

Times Have Changed: FDA Ends ESA REMS Ahead Of First Biosimilars

Apr 17 2017

Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

May 16 2017

HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority

Nov 13 2017

Q&A With US FDA Commissioner Scott Gottlieb

Nov 09 2017

More ANDAs To Be Eligible For Priority Review, Gottlieb Says

Nov 08 2017

Alex Azar And The Return Of Republican-Style Price Negotiation

Nov 24 2017

Pfizer’s EPO Biosimilar Stalls In US On Hospira Compliance Woes

Jun 22 2017

Related Companies

Eli Lilly and Company

Amgen, Inc.

Johnson & Johnson

Hospira, Inc.

Pfizer Inc.

Additional Topics

United States Generic Drugs Pricing Debate Regulation Risk Management BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window